These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32951486)

  • 1. Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia.
    Mushtaq MU; Harrington AM; Chaudhary SG; Michaelis LC; Carlson KB; Abedin S; Runass L; Callander NS; Fallon MJ; Juckett M; Hall AC; Hematti P; Mattison RJ; Atallah EL; Guru Murthy GS
    Leuk Lymphoma; 2021 Jan; 62(1):158-166. PubMed ID: 32951486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after 'CLAG-M' vs. 'MEC'.
    Scheckel CJ; Meyer M; Betcher JA; Al-Kali A; Foran J; Palmer J
    Leuk Res; 2020 Mar; 90():106300. PubMed ID: 32018118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
    Bao Y; Zhao J; Li ZZ
    Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-induction with modified CLAG regimen in relapsed or refractory acute myeloid leukemia in children bridging to allogeneic hematopoietic stem cell transplantation.
    Zhang N; Shao JB; Li H; Yang JW; Chen K; Zhu JS; Jiang H
    World J Pediatr; 2020 Apr; 16(2):152-158. PubMed ID: 31748985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy.
    Ruan M; Liu LP; Zhang AL; Quan Qi B; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
    Cancer Med; 2021 Feb; 10(3):956-964. PubMed ID: 33491298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.
    Price SL; Lancet JE; George TJ; Wetzstein GA; List AF; Ho VQ; Fernandez HF; Pinilla-Ibarz J; Kharfan-Dabaja MA; Komrokji RS
    Leuk Res; 2011 Mar; 35(3):301-4. PubMed ID: 21109304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children.
    Zhang N; Li H; Wang D; Wang Z; Zhu JS; Chen K; Jiang H; Shao JB; Cai C
    Clin Epigenetics; 2024 May; 16(1):63. PubMed ID: 38725010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia.
    Yao H; Zhang C; Tan X; Li J; Yin X; Deng X; Chen T; Rao J; Gao L; Kong P; Zhang X
    Cancer Med; 2023 Jun; 12(11):12377-12387. PubMed ID: 37161845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
    Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
    Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis.
    Cao S; Tao Q; Wang J; Zhang Q; Dong Y
    Medicine (Baltimore); 2023 Nov; 102(44):e34949. PubMed ID: 37933074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [CLAG±DAC regimen in the treatment of refractory/relapsed acute myeloid leukemia].
    Hua WX; Yao WQ; Zhou M; Qi JQ; Kang HZ; Wang RJ; Cai CS; Liu YJ; Wu DP; Han Y
    Zhonghua Xue Ye Xue Za Zhi; 2024 Sep; 45(9):838-843. PubMed ID: 39414607
    [No Abstract]   [Full Text] [Related]  

  • 13. A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML.
    Muluneh B; Buhlinger K; Deal AM; Zeidner JF; Foster MC; Jamieson KJ; Bates J; Van Deventer HW
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e13-e18. PubMed ID: 29100976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Efficacy and Prognostic Factors of CLAG Treatment in Chinese Patients with Refractory or Relapsed Acute Myeloid Leukemia.
    Wang L; Xu J; Tian X; Lv T; Yuan G
    Acta Haematol; 2019; 141(1):43-53. PubMed ID: 30517910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of cladribine, cytarabine, and G-CSF (CLAG) as a bridging therapy prior to allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia.
    Cui T; Li H; Zhou S; Li J; Zhu Q; Zhu W; Tang Z; Ma X; Qiu H; Wu D; Wu X
    Ann Hematol; 2024 Jul; 103(7):2463-2473. PubMed ID: 38758360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colonystimulating factor (CLAG) regime in patients with refractory or relapsed acute myeloid leukemia].
    Duan MH; Zhang Y; Zhang M; Han X; Zhang Y; Yang C; Feng J; Zhang L; Zhang W; Li J; Tian LP; Zhang Y; Zhou DB
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):571-5. PubMed ID: 27535856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CLAG Regimen Composed of Continuous Intravenous Infusion of Cladribine in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia].
    Mi RH; Chen L; Yang HP; Wang XJ; Guo SL; Shi L; Yin QS; Wei XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):333-338. PubMed ID: 33812396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
    Wrzesień-Kuś A; Robak T; Lech-Marańda E; Wierzbowska A; Dmoszyńska A; Kowal M; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Maj S; Hellmann A; Skotnicki A; Jedrzejczak W; Kuliczkowski K;
    Eur J Haematol; 2003 Sep; 71(3):155-62. PubMed ID: 12930315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report.
    Jin M; Hu Y; Wu W; Luo Y; Tan Y; Yu J; Jin A; Yang L; Huang H; Wei G
    BMC Cancer; 2019 Mar; 19(1):242. PubMed ID: 30885156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.
    Mirza AS; Lancet JE; Sweet K; Padron E; Pinilla-Ibarz J; Nardelli L; Cubitt C; List AF; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):902-907. PubMed ID: 29030092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.